Unity's stock has surged on optimism around Vector, despite ongoing financial weakness. Vector is delivering strong sequential Ad Network growth, but questions remain about the scalability of customer ...
SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...
UBX1325 averaged a 5.2 letter increase in best-corrected visual acuity at 24 weeks and a 5.5 letter increase at 36 weeks in the ASPIRE trial. With exception for the average of weeks 20 and 24, when it ...
Unity Biotechnology, Inc. UBX stock plummeted on Monday after the company released results from its latest study. The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback